CFH,VEGFandHTRA1promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration

McKibbin, Martin; Ali, Manir; Bansal, Shveta; Baxter, Paul D.; West, K.; Williams, G.; Cassidy, Frances; Inglehearn, Chris F.

doi:10.1136/bjo.2010.193680

Cited by 95 publications

(89 citation statements)

References 28 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk factors for AMD include age, smoking, systemic arterial hypertension (SAH), high serum cholesterol, and substantial alcohol consumption. In addition, studies have provided evidence indicating the important role of genetic factors in the physiopathology of AMD (7) . Recently, a number of studies have evaluated the relationship between vascular endothelial growth factor (VEGF) polymorphisms and AMD genetic susceptibility variants (4) .…”

Section: Introductionmentioning

confidence: 99%

Influence of VEGF-C936T genetic variant on age-related macular degeneration

Gonçalves¹,

Cezario²,

Calastri³

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Influence of VEGF-C936T genetic variant on age-related macular degeneration

Gonçalves¹,

Cezario²,

Calastri³

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

“…Thereby, gene polymophisms of the VEGF-A (rs3025000), complement factor H (rs1061170), age-related macular susceptibility 2 (rs10490924), and high-temperature requirement A-1 (rs11200638) were determined to influence the therapeutic outcome. 16,[39][40][41] Likewise, the gene polymorphisms rs12913832 and rs1129038 were identified to influence the iris color. 42 The interaction of gene polymorphisms associated to iris color and the anti-VEGF responsiveness has not been investigated yet.…”

Section: Discussionmentioning

confidence: 99%

“…[11][12][13] In this context, predictive baseline characteristics such as visual acuity, central retinal thickness, lesion size, choroidal neovascularization type, duration of symptoms, genotype, and coincidental systemic factors were identified. [14][15][16][17] However, taking known influencing parameters into account by adapting therapy regimes individually, the diversity of the outcome after anti-VEGF therapy is still remarkable. 18,19 Accordingly, the purpose of this study was to investigate the influence of seasonal sunlight intensity and patients' iris color on the visual recovery after initial anti-VEGF therapy with ranibizumab or bevacizumab for neovascular AMD.…”

Section: Introductionmentioning

confidence: 99%

Influence of seasonal sunlight intensity and iris color on the anti-VEGF therapy for neovascular age-related macular degeneration

Brockmann

Dawczynski

2013

Eye

View full text Add to dashboard Cite

Purpose To investigate the influence of seasonal light intensity and patients' iris color on the visual recovery after antivascular endothelial growth factor (VEGF) therapy with ranibizumab or bevacizumab for neovascular age-related macular degeneration (AMD). Methods The visual acuity of 555 eyes (529 patients) with neovascular AMD was evaluated after intravitreal injections of either ranibizumab or bevacizumab in respect to global radiation intensity and iris color. Results The functional results during anti-VEGF therapy revealed a seasonal oscillation with a negative correlation between visual recovery and global radiation intensity (R 2 ¼ À 0.756, P ¼ 0.004). Although the influence of the sunlight intensity on the visual recovery was significant after the first injection, this effect vanished within the continuous course of treatment. Regarding the improvement of functional recovery depending on iris color, dark-colored eyes (16.0%) gained 8.5 ± 10.0 letters after the first injection and 9.9 ± 12.8 letters after the second injection, compared with 3.4 ± 8.6 letters and 4.4±11.0 letters in light-colored eyes (84.0%), respectively (P ¼ 0.005 and P ¼ 0.019).Conclusions Our results indicate that seasonal sunlight intensity and iris color might influence the visual recovery of neovascular AMD patients undergoing anti-VEGF therapy. Our findings may be used as suggestions to refine individual anti-VEGF therapy regimens, especially in patients with light-colored eyes.

show abstract

“…The genotypes of rs1413711 were found to be indicators of anti-VEGF response in a UK study by McKibbin group (McKibbin et al, 2012), but other studies did not find this to be the case (Boltz et al, 2012;Yuan et al, 2013;Fauser and Lambrou, 2014). In the UK study, the presence of a C nucleotide at rs1413711 was associated with a marked improvement in visual acuity (McKibbin et al, 2012) and it had a maximum followup time of six months, whereas some of the other studies had longer durations. It is then possible that there is a statistically significant effect at month six of treatment, which decreases to a non-significant level by month twelve or month fifteen (Fauser and Lambrou, 2014).…”

Section: Association Of Vegf Polymorphisms With Disease Riskmentioning

confidence: 99%

Vascular Endothelial Growth Factor: An Overview Across Multiple Disease Conditions

Canavese¹

2015

American Journal of Pharmacology and Toxicology

View full text Add to dashboard Cite

Vascular Endothelial Growth Factor (VEGF) is the major player in the regulation of physiological angiogenesis as well as it has also been implicated in pathological angiogenesis, associated with cancers and other conditions, among which psoriasis, autoimmune diseases and visual loss in macular degeneration. Interestingly, three regulatory Single Nucleotide Polymorphisms (rSNPs) in the promoter region of VEGF-A gene have been significantly associated with different human diseases and it is possible that, in the near future, the cumulative effect of several high-risk Single Nucleotide Polymorphisms (SNPs) may prove useful in a clinical setting. Currently, new VEGF inhibitors are undergoing clinical testing in various disease conditions, given that VEGF inhibition has also been contemplated as a possible strategy for prevention of angiogenesis and vascular leakage to decrease inflammation. This review focuses mainly on the role of Vascular Endothelial Growth Factor in several pathological contexts, highlighting the emerging association of the most common VEGF polymorphisms with disease risk. An update on the therapeutic implications of VEGF has also been documented.

show abstract

CFH,VEGFandHTRA1promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration

Abstract: This study reports preliminary evidence suggesting that the higher AMD risk genotypes in CFH, VEGF and HTRA1 may influence the short-term response to treatment with ranibizumab for neovascular AMD.

Cited by 95 publications

References 28 publications

Influence of VEGF-C936T genetic variant on age-related macular degeneration

Influence of VEGF-C936T genetic variant on age-related macular degeneration

Influence of seasonal sunlight intensity and iris color on the anti-VEGF therapy for neovascular age-related macular degeneration

Vascular Endothelial Growth Factor: An Overview Across Multiple Disease Conditions

Contact Info

Product

Resources

About